바이온드스프링(BYSI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.72 (+1.72%), 시가총액 $0.05B, 52주 최저~최고 $1.27 ~ $3.40.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth fac
바이온드스프링의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
바이온드스프링의 현재 주가는 $0.72 (+1.72%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
바이온드스프링의 시가총액은 약 $0.05B입니다.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates thr